Results 291 to 300 of about 119,936 (354)
Some of the next articles are maybe not open access.
TIPS - Trends in Pharmacological Sciences, 2022
Doxorubicin (DOX) is a chemotherapeutic drug that is utilized for solid tumors and hematologic malignancies, but its clinical application is hampered by life-threatening cardiotoxicity including cardiac dilation and heart failure.
Lin Wu +4 more
semanticscholar +1 more source
Doxorubicin (DOX) is a chemotherapeutic drug that is utilized for solid tumors and hematologic malignancies, but its clinical application is hampered by life-threatening cardiotoxicity including cardiac dilation and heart failure.
Lin Wu +4 more
semanticscholar +1 more source
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
Circulation, 2015 Background— Three types of anthracycline-induced cardiotoxicities are currently recognized: acute, early-onset chronic, and late-onset chronic. However, data supporting this classification are lacking.
Daniela Maria Cardinale +2 more
exaly +2 more sources
Annals of Emergency Medicine, 1988
Prolongation of the QRS interval, cardiopulmonary arrest, and death in a 31-year-old woman following an overdose of 2 g amoxapine, a tricyclic antidepressant, is reported. The patient's QRS interval prolonged to beyond 100 ms throughout hospitalization.
M A, Munger, B A, Effron
openaire +2 more sources
Prolongation of the QRS interval, cardiopulmonary arrest, and death in a 31-year-old woman following an overdose of 2 g amoxapine, a tricyclic antidepressant, is reported. The patient's QRS interval prolonged to beyond 100 ms throughout hospitalization.
M A, Munger, B A, Effron
openaire +2 more sources
Expert Opinion on Drug Safety, 2006
The use of anthracyclines is limited by dose-dependent cardiotoxicity. Three forms of anthracycline cardiotoxicity are described; an immediate pericarditis-myocarditis syndrome, an early onset chronic progressive CHF developing during or shortly after therapy and late-onset cardiotoxicity presenting years following treatment.
Robin L, Jones +2 more
openaire +2 more sources
The use of anthracyclines is limited by dose-dependent cardiotoxicity. Three forms of anthracycline cardiotoxicity are described; an immediate pericarditis-myocarditis syndrome, an early onset chronic progressive CHF developing during or shortly after therapy and late-onset cardiotoxicity presenting years following treatment.
Robin L, Jones +2 more
openaire +2 more sources
Phytomedicine, 2023
BACKGROUND Doxorubicin (DOX) is a potent anticancer chemotherapeutic agent whose clinical application is substantially constrained by its cardiotoxicity.
Guangyao Fang +8 more
semanticscholar +1 more source
BACKGROUND Doxorubicin (DOX) is a potent anticancer chemotherapeutic agent whose clinical application is substantially constrained by its cardiotoxicity.
Guangyao Fang +8 more
semanticscholar +1 more source
Current problems in cardiology, 2023
As medicine advances to employ sophisticated anticancer agents to treat a vast array of oncological conditions, it is worth considering side effects associated with several chemotherapeutics.
Toufik Abdul-Rahman +11 more
semanticscholar +1 more source
As medicine advances to employ sophisticated anticancer agents to treat a vast array of oncological conditions, it is worth considering side effects associated with several chemotherapeutics.
Toufik Abdul-Rahman +11 more
semanticscholar +1 more source
2007
The clinical use of doxorubicin and other quinone-hydroquinone anticancer anthracyclines is limitedby a dose-related cardiotoxicity. Here, we review the correlation of cardiotoxicity of doxorubicinwith its peak plasma concentration and diffusion in the heart, followed by reductive bioactivation or oxidativeinactivation.
Pierantonio, Menna +3 more
openaire +2 more sources
The clinical use of doxorubicin and other quinone-hydroquinone anticancer anthracyclines is limitedby a dose-related cardiotoxicity. Here, we review the correlation of cardiotoxicity of doxorubicinwith its peak plasma concentration and diffusion in the heart, followed by reductive bioactivation or oxidativeinactivation.
Pierantonio, Menna +3 more
openaire +2 more sources
Cyclophosphamide cardiotoxicity
European Journal of Pediatrics, 1980A 12-year-old boy with aplastic anemia developed severe but reversible cardiac failure after treatment with 200 mg/kg cyclophosphamide (4 x 50 mg/kg on four consecutive days) given as preparation for bone marrow grafting. This and previously reported cases demonstrate the possibility of cardiotoxicity after high doses of the drug.
G, von Bernuth +6 more
openaire +2 more sources
Emergency Medicine Clinics of North America, 1995
This article describes the cardiovascular effects and treatment of patients who have used cardiotoxic drugs. The discussion includes cocaine, methamphetamine, cyclic antidepressants, calcium channel blockers, beta-blockers, and digoxin. The authors review treatment controversies and emphasize the acute aspects of toxicity commonly seen in the emergency
R W, Derlet, B Z, Horowitz
openaire +2 more sources
This article describes the cardiovascular effects and treatment of patients who have used cardiotoxic drugs. The discussion includes cocaine, methamphetamine, cyclic antidepressants, calcium channel blockers, beta-blockers, and digoxin. The authors review treatment controversies and emphasize the acute aspects of toxicity commonly seen in the emergency
R W, Derlet, B Z, Horowitz
openaire +2 more sources
Oxidative stress injury in doxorubicin-induced cardiotoxicity.
Toxicology Letters, 2019Doxorubicin (DOX) is widely used as a broad-spectrum anti-tumor anthracycline to treat various cancers. The serious adverse effects of DOX on cardiotoxicity limit its clinical application.
Songbo Mei +5 more
semanticscholar +1 more source